Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma

Bone Marrow Transplant. 2023 Oct;58(10):1143-1145. doi: 10.1038/s41409-023-02025-0. Epub 2023 Jun 30.

Authors

Tamer Othman¹, Robert Lowsky², Carol Richman¹, Rasmus Hoeg¹, Mehrdad Abedi¹, Joseph Tuscano³

Affiliations

¹ University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
² Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
³ University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. [email protected].

PMID: 37391654
DOI: 10.1038/s41409-023-02025-0

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Non-Hodgkin* / pathology
Lymphoma, Non-Hodgkin* / therapy
Radioimmunotherapy
Yttrium Radioisotopes / therapeutic use

Substances

Yttrium-90
ibritumomab tiuxetan
Yttrium Radioisotopes